Payment overview · 2025
General Payments
$651.49
39 reported records · 11 companies
Healthcare provider profile · identity verified
James Scott Bridges, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HOT SPRINGS, AR · NPI 1821037060
Verified facts
What the public records show
CMS Open Payments records show James Scott Bridges, M.D. received $651.49 in general payments during 2025 across 39 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Mounjaro by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 84 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $213.67 | 32.8% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $161.15 | 24.7% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $66.43 | 10.2% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $65.42 | 10.0% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $32.23 | 5.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.68 | 4.4% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.68 | 3.2% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $17.14 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.10 | 2.5% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $15.09 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.90 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $651.49 | 39 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $92.78 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $92.78 | 7 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $81.79 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $81.06 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $51.87 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.82 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $49.22 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $43.66 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $32.23 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $28.68 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.68 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.76 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.68 | 1 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $17.21 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.50 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $16.10 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $15.09 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 84 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 37 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 94 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 60 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
60 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
37 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
94 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
84 | 22 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
12 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 477 | 127 |
| Atorvastatin Calcium | Atorvastatin Calcium | 471 | 142 |
| Omeprazole | Omeprazole | 414 | 113 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 411 | 99 |
| Amlodipine Besylate | Amlodipine Besylate | 349 | 96 |
| Gabapentin | Gabapentin | 317 | 87 |
| Lisinopril | Lisinopril | 312 | 93 |
| Trazodone Hcl | Trazodone Hcl | 260 | 67 |
| Pantoprazole Sodium | Pantoprazole Sodium | 249 | 70 |
| Furosemide | Furosemide | 247 | 71 |
| Alprazolam | Alprazolam | 241 | 44 |
| Losartan Potassium | Losartan Potassium | 235 | 65 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 204 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 192 | 55 |
| Escitalopram Oxalate | Escitalopram Oxalate | 188 | 41 |
| Potassium Chloride | Potassium Chloride | 185 | 47 |
| Clonazepam | Clonazepam | 176 | 42 |
| Metformin Hcl | Metformin Hcl | 175 | 51 |
| Diclofenac Sodium | Diclofenac Sodium | 170 | 58 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 168 | 59 |
| Tramadol Hcl | Tramadol Hcl | 163 | 58 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 162 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 35 |
| Tamsulosin Hcl | Tamsulosin Hcl | 152 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 145 | 36 |
| Meloxicam | Meloxicam | 137 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 135 | 38 |
| Sertraline Hcl | Sertraline Hcl | 135 | 32 |
| Lorazepam | Lorazepam | 125 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 120 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 109 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 31 |
| Metoprolol Tartrate | Metoprolol Tartrate | 98 | 31 |
| Ozempic | Semaglutide | 94 | 19 |
| Temazepam | Temazepam | 94 | 19 |
| Carvedilol | Carvedilol | 92 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 90 | 21 |
| Azithromycin | Azithromycin | 89 | 77 |
| Allopurinol | Allopurinol | 85 | 23 |
| Eliquis | Apixaban | 84 | 22 |
| Montelukast Sodium | Montelukast Sodium | 84 | 23 |
| Spironolactone | Spironolactone | 83 | 21 |
| Fluoxetine Hcl | Fluoxetine Hcl | 82 | 19 |
| Simvastatin | Simvastatin | 82 | 27 |
| Pregabalin | Pregabalin | 81 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 80 | 16 |
| Buspirone Hcl | Buspirone Hcl | 77 | 23 |
| Oxycodone Hcl | Oxycodone Hcl | 75 | 12 |
| Atenolol | Atenolol | 73 | 20 |
| Alendronate Sodium | Alendronate Sodium | 72 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 71 | 52 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 11 |
| Bupropion Xl | Bupropion Hcl | 67 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 22 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 67 | 12 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 67 | 14 |
| Ondansetron Odt | Ondansetron | 65 | 34 |
| Diazepam | Diazepam | 63 | 19 |
| Estradiol | Estradiol | 60 | 15 |
| Famotidine | Famotidine | 60 | 21 |
| Methylprednisolone | Methylprednisolone | 60 | 45 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 59 | 26 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 57 | 48 |
| Ibuprofen | Ibuprofen | 56 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 14 |
| Baclofen | Baclofen | 55 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 23 |
| Xarelto | Rivaroxaban | 55 | suppressed |
| Glipizide Er | Glipizide | 53 | 15 |
| Ezetimibe | Ezetimibe | 52 | 17 |
| Glipizide | Glipizide | 52 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 52 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 52 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 51 | 38 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 45 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 41 |
| Farxiga | Dapagliflozin Propanediol | 43 | suppressed |
| Primidone | Primidone | 43 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 42 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 13 |
| Irbesartan | Irbesartan | 40 | 12 |
| Meclizine Hcl | Meclizine Hcl | 40 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 38 | suppressed |
| Mirtazapine | Mirtazapine | 38 | suppressed |
| Jardiance | Empagliflozin | 37 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 36 | suppressed |
| Fluconazole | Fluconazole | 36 | 20 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 35 | suppressed |
| Eszopiclone | Eszopiclone | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Mounjaro | Tirzepatide | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | 11 |
| Memantine Hcl | Memantine Hcl | 30 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 29 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 29 | suppressed |
| Finasteride | Finasteride | 28 | suppressed |
| Nystatin | Nystatin | 28 | 17 |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 25 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Topiramate | Topiramate | 23 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Invokana | Canagliflozin | 22 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 18 |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Digoxin | Digoxin | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 19 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 19 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 19 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 15 | suppressed |
| Celecoxib | Celecoxib | 15 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 14 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dutasteride | Dutasteride | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Insulin Lispro | Insulin Lispro | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 12 | 11 |
| Tramadol Hcl Er | Tramadol Hcl | 12 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Paliperidone Er | Paliperidone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $651.49 · 39 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, JARDIANCE, KISUNLA, MOUNJARO, NUCALA, NURTEC ODT, Ozempic, QULIPTA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, UBRELVY, VRAYLAR, XIFAXAN, ZEPBOUND, ZORYVE | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error